BBNX
Beta Bionics, Inc.
$13.87
-0.14%
$641.2M
No data for this timeframe.
Vol
Market Cap$641.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (78%)
Inst. Holders8 funds
Inst. Value$221.2M
Inst. Activity4 buys / 1 sells
Insider Activity0B / 19S
Insider Net $-$774.3K
SEC Reports8
Press Releases1
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001674632·Prev Close $13.89
Recent Activity
Jun 5, 2026
SEC
Five senior insiders at Beta Bionics, including the CEO, CFO, and CMO, collectively sold $409K in open-market sales on J
CLUSTER — Impact 3/10
Jun 4, 2026
Insider
Jones Christy sold 2,811 shares
Director @ $14.00 ($39.4K)
Jun 4, 2026
Insider
Hopman Mark sold 275 shares
Chief Commercial Officer @ $12.31 ($3.4K)
Jun 3, 2026
SEC
Four top executives at Beta Bionics, including the CEO and CFO, sold a combined $417K in open-market sales on June 2, 20
CLUSTER — Impact 3/10
Jun 2, 2026
Insider
Saint Sean sold 16,872 shares
President & CEO @ $12.61 ($212.7K)
May 26, 2026
SEC
Two directors at Beta Bionics sold a combined $30K in open-market sales on May 21, 2026, while five directors received n
CLUSTER — Impact 2/10
Inst.
BANK OF AMERICA CORP — DOUBLED
432,340 shares ($13.2M)
Inst.
TWO SIGMA INVESTMENTS, LP — DOUBLED
410,603 shares ($12.5M)
Price Targets
$19.18
+33.3% upside
Strong Buy
Current $14.39
Low $13.00
Median $18.00
High $32.00
11 analysts
$13.00
$32.00
Analyst Ratings
6Strong Buy
8Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | Goldman Sachs | MAINTAIN | Buy → Buy |
| May 18, 2026 | B of A Securities | MAINTAIN | Neutral → Neutral |
| Apr 22, 2026 | Leerink Partners | MAINTAIN | Outperform → Outperform |
| Apr 22, 2026 | Stifel | MAINTAIN | Buy → Buy |
| Apr 15, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.55 ▼ -19.5% | $-0.66 — $-0.46 | -100% YoY | 3 |
| Next Q | $-0.53 ▼ -19.0% | $-0.57 — $-0.49 | -60% YoY | 3 |
| Current FY | $-2.11 ▼ -18.9% | $-2.38 — $-1.79 | -53% YoY | 3 |
| Next FY | $-2.39 ▼ -23.3% | $-2.65 — $-2.19 | -13% YoY | 3 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Five senior insiders at Beta Bionics, including the CEO, CFO, and CMO, collectively sold $409K in open-market sales on J
Jun 5, 2026
NEUTRAL
CLUSTER
3/10
Four top executives at Beta Bionics, including the CEO and CFO, sold a combined $417K in open-market sales on June 2, 20
Jun 3, 2026
NEUTRAL
Press
3/10
Beta Bionics announced it will release its Q1 2026 financial results on April 21, 2026, followed by a conference call. T
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $105.4M | ADD |
| VANGUARD GROUP INC | $67.6M | DOUBLED |
| BANK OF AMERICA CORP | $13.2M | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $12.5M | DOUBLED |
| NORGES BANK | $10.3M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Jones Christy | SELL | $39.4K |
| Jun 4, 2026 | Hopman Mark | SELL | $3.4K |
| Jun 2, 2026 | Saint Sean | SELL | $212.7K |
| Jun 2, 2026 | Russell Steven | SELL | $53.2K |
| Jun 2, 2026 | Feider Stephen | SELL | $84.2K |
8 institutional holders with $221.2M total value (7,258,980 shares) as of 2025-Q4. Top holders: MORGAN, VANGUARD, BANK. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 3,459,453 | $105.4M | 47.7% | ADD +27.5% |
| 2 | VANGUARD GROUP INC | 2,218,238 | $67.6M | 30.6% | DOUBLED +213.5% |
| 3 | BANK OF AMERICA CORP /DE/ | 432,340 | $13.2M | 6.0% | DOUBLED +118.7% |
| 4 | TWO SIGMA INVESTMENTS, LP | 410,603 | $12.5M | 5.7% | DOUBLED +150.7% |
| 5 | NORGES BANK | 339,300 | $10.3M | 4.7% | NEW |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 331,623 | $10.1M | 4.6% | DOUBLED +223.5% |
| 7 | WELLS FARGO & COMPANY/MN | 50,312 | $1.5M | 0.7% | ADD +57.5% |
| 8 | FMR LLC | 17,111 | $521.4K | 0.2% | DOUBLED +137.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 197,707 | 432,340 | +118.7% | $13.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 163,764 | 410,603 | +150.7% | $12.5M | 2025-Q4 |
| NORGES BANK | NEW | — | 339,300 | — | $10.3M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 31,954 | 50,312 | +57.5% | $1.5M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 22,500 | 0 | -100.0% | $0.00 | 2025-Q4 |
| MORGAN STANLEY | ADD | 2,949,365 | 3,761,583 | +27.5% | $74.7M | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 706,968 | 2,216,185 | +213.5% | $44.0M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 102,225 | 330,692 | +223.5% | $6.6M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 72,245 | 197,707 | +173.7% | $3.9M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 21,296 | 163,764 | +669.0% | $3.3M | 2025-Q3 |
| UBS Group AG | ADD | 96,061 | 127,905 | +33.1% | $2.5M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 15,020 | 31,954 | +112.7% | $634.9K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 16,500 | 22,500 | +36.4% | $447.1K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 1,401,653 | 2,949,365 | +110.4% | $42.9M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 16,500 | — | $240.2K | 2025-Q2 |
| FMR LLC | DOUBLED | 6,883 | 16,377 | +137.9% | $238.4K | 2025-Q2 |
| MORGAN STANLEY | NEW | — | 1,401,653 | — | $17.2M | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 946,350 | — | $11.6M | 2025-Q1 |
| VANGUARD GROUP INC | NEW | — | 709,255 | — | $8.7M | 2025-Q1 |
| UBS Group AG | NEW | — | 124,340 | — | $1.5M | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 101,614 | — | $1.2M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 20,751 | — | $254.0K | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | NEW | — | 15,820 | — | $193.6K | 2025-Q1 |
| FMR LLC | NEW | — | 6,883 | — | $84.2K | 2025-Q1 |
11 unique insiders with 19 transactions. Net insider value: -$774.3K ($0.00 bought, $774.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Jones Christy | Director | SELL | 2,811 | $14.00 | $39.4K |
| Jun 4, 2026 | Hopman Mark | Chief Commercial Officer | SELL | 275 | $12.31 | $3.4K |
| Jun 2, 2026 | Saint Sean | President & CEO | SELL | 16,872 | $12.61 | $212.7K |
| Jun 2, 2026 | Russell Steven Jon | Chief Medical Officer | SELL | 4,222 | $12.61 | $53.2K |
| Jun 2, 2026 | Feider Stephen | Chief Financial Officer | SELL | 6,676 | $12.61 | $84.2K |
| Jun 2, 2026 | Hopman Mark | Chief Commercial Officer | SELL | 5,329 | $12.61 | $67.2K |
| Jun 2, 2026 | Mensinger Mike | Chief Product Officer | SELL | 4,378 | $12.61 | $55.2K |
| May 22, 2026 | Lezack Adam | Director | SELL | 998 | $11.21 | $11.2K |
| May 21, 2026 | Dearen Danny L. | Director | A | 16,965 | $0.00 | $0.00 |
| May 21, 2026 | CARNEY SEAN | Director | A | 16,965 | $0.00 | $0.00 |
| May 21, 2026 | Jones Christy | Director | A | 16,965 | $0.00 | $0.00 |
| May 21, 2026 | Jones Christy | Director | SELL | 1,998 | $9.95 | $19.9K |
| May 21, 2026 | Palasis Maria | Director | A | 16,965 | $0.00 | $0.00 |
| May 21, 2026 | Lezack Adam | Director | SELL | 1,000 | $9.95 | $9.9K |
| May 21, 2026 | Lezack Adam | Director | A | 16,965 | $0.00 | $0.00 |
| May 21, 2026 | MICHEL GERARD J | Director | A | 16,965 | $0.00 | $0.00 |
| Mar 4, 2026 | Hopman Mark | Chief Commercial Officer | SELL | 353 | $11.57 | $4.1K |
| Mar 2, 2026 | Mensinger Mike | Chief Product Officer | SELL | 1,064 | $12.36 | $13.2K |
| Mar 2, 2026 | Hopman Mark | Chief Commercial Officer | SELL | 834 | $12.36 | $10.3K |
| Mar 2, 2026 | Russell Steven Jon | Chief Medical Officer | SELL | 1,026 | $12.36 | $12.7K |
| Mar 2, 2026 | Saint Sean | President & CEO | SELL | 3,384 | $12.36 | $41.8K |
| Mar 2, 2026 | Feider Stephen | Chief Financial Officer | SELL | 1,428 | $12.36 | $17.7K |
| Feb 27, 2026 | Russell Steven Jon | Chief Medical Officer | A | 109,105 | $0.00 | $0.00 |
| Feb 27, 2026 | Saint Sean | President & CEO | A | 343,269 | $0.00 | $0.00 |
| Feb 27, 2026 | Saint Sean | President & CEO | A | 184,837 | $0.00 | $0.00 |
| Feb 27, 2026 | Feider Stephen | Chief Financial Officer | A | 131,543 | $0.00 | $0.00 |
| Feb 27, 2026 | Mensinger Mike | Chief Product Officer | A | 58,749 | $0.00 | $0.00 |
| Feb 27, 2026 | Hopman Mark | Chief Commercial Officer | A | 109,105 | $0.00 | $0.00 |
| Feb 27, 2026 | Mensinger Mike | Chief Product Officer | A | 91,520 | $0.00 | $0.00 |
| Feb 27, 2026 | Hopman Mark | Chief Commercial Officer | A | 91,520 | $0.00 | $0.00 |
| Feb 27, 2026 | Feider Stephen | Chief Financial Officer | A | 110,342 | $0.00 | $0.00 |
| Feb 27, 2026 | Russell Steven Jon | Chief Medical Officer | A | 91,520 | $0.00 | $0.00 |
| Feb 27, 2026 | Russell Steven Jon | Chief Medical Officer | A | 58,749 | $0.00 | $0.00 |
| Feb 27, 2026 | Saint Sean | President & CEO | A | 287,944 | $0.00 | $0.00 |
| Feb 27, 2026 | Feider Stephen | Chief Financial Officer | A | 70,831 | $0.00 | $0.00 |
| Feb 27, 2026 | Mensinger Mike | Chief Product Officer | A | 109,105 | $0.00 | $0.00 |
| Feb 27, 2026 | Hopman Mark | Chief Commercial Officer | A | 58,749 | $0.00 | $0.00 |
| Dec 4, 2025 | Hopman Mark | Chief Commercial Officer | SELL | 2,061 | $30.66 | $63.2K |
| Dec 2, 2025 | Russell Steven Jon | Chief Medical Officer | SELL | 1,025 | $29.34 | $30.1K |
| Dec 2, 2025 | Hopman Mark | Chief Commercial Officer | SELL | 856 | $29.34 | $25.1K |
8 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 6 neutral. Avg impact: 4.0/10.
NEUTRAL
CLUSTER
3/10
Five senior insiders at Beta Bionics, including the CEO, CFO, and CMO, collectively sold $409K in op
Jun 5, 2026
NEUTRAL
CLUSTER
3/10
Four top executives at Beta Bionics, including the CEO and CFO, sold a combined $417K in open-market
Jun 3, 2026
NEUTRAL
CLUSTER
2/10
Two directors at Beta Bionics sold a combined $30K in open-market sales on May 21, 2026, while five
May 26, 2026
BULLISH
8-K
8/10
Beta Bionics reported strong Q1 2026 revenue growth of 57% year-over-year and raised full-year 2026
Apr 21, 2026
BULLISH
PRESS-RELEASE
8/10
Beta Bionics (BBNX) reported Q1 2026 revenue of $27.6 million, up 57% YoY and above $27.0M consensus
Apr 21, 2026
NEUTRAL
DEFA14A
2/10
Beta Bionics, Inc. (BBNX) is holding its 2026 Annual Meeting of Stockholders to elect two Class I di
Apr 10, 2026
NEUTRAL
CLUSTER
3/10
Six Beta Bionics executives, including the CEO, CFO, and other C-suite officers, sold shares in a co
Mar 6, 2026
NEUTRAL
CLUSTER
3/10
Seven days of insider activity at Beta Bionics (BBNX) show coordinated open-market share sales by fi
Mar 3, 2026
Current analyst consensus: Buy (78% buy). Based on 18 analysts: 6 strong buy, 8 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$19.18 mean target
+33.3% upside
Strong Buy (1.64)
$13.00 Low
$32.00 High
| Metric | Value |
|---|---|
| Current Price | $14.39 |
| Target Low | $13.00 |
| Target Mean | $19.18 |
| Target Median | $18.00 |
| Target High | $32.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.64) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.55 | $-0.66 | $-0.46 | -99.8% | -19.5% | 0↑ 1↓ | $0.0B | 35.8% | 3 |
| Next Q 2026-09-30 |
$-0.53 | $-0.57 | $-0.49 | -59.6% | -19.0% | 0↑ 1↓ | $0.0B | 28.8% | 3 |
| Current FY 2026-12-31 |
$-2.11 | $-2.38 | $-1.79 | -52.9% | -18.9% | 0↑ 1↓ | $0.1B | 33.3% | 3 |
| Next FY 2027-12-31 |
$-2.39 | $-2.65 | $-2.19 | -13.5% | -23.3% | 0↑ 1↓ | $0.2B | 35.3% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.547 | |
| 7d ago | $-0.547 | |
| 30d ago | $-0.458 | -0.089 |
| 60d ago | $-0.458 | -0.089 |
| 90d ago | $-0.458 | -0.089 |
8 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | Goldman Sachs | MAINTAIN | Buy | Buy |
| May 18, 2026 | B of A Securities | MAINTAIN | Neutral | Neutral |
| Apr 22, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 22, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Apr 15, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Apr 9, 2026 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | Baird | MAINTAIN | Neutral | Neutral |
| Feb 4, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 27, 2026 | TD Cowen | INITIATE | — | Hold |
| Jan 9, 2026 | Lake Street | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Dec 18, 2025 | Truist Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 8 | 4 | 0 | 0 | 78% | |
| May 1, 2026 | 6 | 8 | 4 | 0 | 0 | 78% | |
| Apr 1, 2026 | 6 | 8 | 4 | 0 | 0 | 78% | |
| Mar 1, 2026 | 6 | 7 | 4 | 0 | 0 | 76% | |
| Feb 1, 2026 | 6 | 7 | 4 | 0 | 0 | 76% | |
| Jan 1, 2026 | 7 | 7 | 2 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
06 MAY 2026 , WHAT ARE THE BIGGEST LOSERS AND WHY ?
▲ 1
💬 1
⚡ 0.2
Apr 27, 2026
other
Beta Bionics to Present at the Bank of America Securities Health Care Conference
<p align="left">IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of adva
Apr 21, 2026
earnings
Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
<p align="left">IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of adva
Apr 21, 2026
earnings_calendar
BBNX Q1 2026 Earnings Scheduled — 2026-04-21
Apr 16, 2026
short_interest
FTD: BBNX — 64,065 shares ($0.8M) failed to deliver
Settlement: 20260416, Price: $13.02, FTD Value: $834,126.3, BETA BIONICS INC COM
Apr 16, 2026
short_volume
Short Volume: BBNX — 58.1% short (0.3M / 0.6M)
Short: 347,907 | Exempt: 0 | TRF Vol: 598,706 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: BBNX — 67.0% short (0.6M / 0.8M)
Short: 561,997 | Exempt: 0 | TRF Vol: 839,155 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
Apr 13, 2026
short_volume
Short Volume: BBNX — 58.8% short (0.3M / 0.5M)
Short: 304,092 | Exempt: 0 | TRF Vol: 517,569 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
Apr 10, 2026
short_volume
Short Volume: BBNX — 65.4% short (0.4M / 0.6M)
Short: 406,991 | Exempt: 240 | TRF Vol: 622,101 | Short Ratio: 65.4% | Off-exchange volume (dark pool + OTC)
Mar 31, 2026
other
Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
Bionic Insights helps HCPs quickly identify key drivers of glucose outcomes, enabling faster decisions and more productive patient discussions.
Mar 31, 2026
short_volume
Short Volume: BBNX — 64.2% short (0.5M / 0.8M)
Short: 543,771 | Exempt: 0 | TRF Vol: 847,390 | Short Ratio: 64.2% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
<p>IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes
Mar 11, 2026
short_interest
FTD: BBNX — 52,746 shares ($0.6M) failed to deliver
Settlement: 20260311, Price: $10.97, FTD Value: $578,623.62, BETA BIONICS INC COM